Early Study Termination Muddles Benefit of Hydrocortisone in COVID-19
Patients with severe COVID-19 may benefit from a fixed-dose or shock-dependent dosing of hydrocortisone, but early study termination hindered definitive conclusions.
Christina Bennett, MS
Christina Bennett, MS, is an independent medical journalist who writes about a variety of medical topics, including oncology, health care policy, and cell and gene therapies. She has a bachelor's degree in biomedical science and a master’s degree in science and technology journalism, both from Texas A&M University. She is a member of the Association of Healthcare Journalists and the National Association of Science Writers and was one of a dozen journalists selected for the 2017 National Cancer Reporting Fellowships.
